Sveikatal is developing drug candidates that can treat major diseases, including type 2 diabetes, fatty liver disease, hyperlipidemia, and cancer. Sveikatal’s discovery and IP platform is based on more than twenty years of cutting-edge research on vitamin A and its metabolites, developed at Cornell University and Weill Cornell Medical College (New York, USA). This program continues to be supported by National Institutes of Health (NIH) and other organizations. Preclinical studies have already